Chinese pharmaceutical company (600056.SH) subsidiary obtains the registration approval for the drug Rosuvastatin Ezetimibe tablets (I).

Intelligence Financial News APP, China Medicine (600056.SH) announced that recently, its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical") has received the "Drug Registration Certificate" for the approval and issuance of Rosuvastatin Ezetimibe Tablets (I) issued by the National Medical Products Administration. Rosuvastatin Ezetimibe Tablets are mainly used for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). The combination of Ezetimibe and Rosuvastatin Calcium can synergistically enhance efficacy, increase lipid-lowering effects, and reduce cardiovascular events.